Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tolerability and efficacy of BMB-101 to treat absence epilepsy and developmental epileptic encephalopathy.
The trial is expected to enroll 20 adults from 18 to 65 years old, Bright Minds said.
Bright Minds and Firefly have previously collaborated to analyze data from the phase 1 trial of BMB-101 using Firefly's BNA technology platform, the company said.
"This compound is not only poised to make a significant impact in both the [developmental epileptic encephalopathy] and absence epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance," said Ian McDonald, Bright Minds chief executive .
Bright Minds shares rose 24% in early trading, while Firefly was up 17%.
Price: 58.74, Change: +11.53, Percent Change: +24.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。